Therapeutic Asset Ratings

329 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- Plasma Cell Myeloma	University Health Network, Toronto	P2	CCC (50)
Anitocabtagene-Autoleucel Plasma Cell Myeloma	Kite, A Gilead Company	P2	CCC (50)
Catequentinib Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (50)
Cemsidomide Plasma Cell Myeloma	C4 Therapeutics, Inc.	P2	CCC (50)
Ciltacabtagene Autoleucel Plasma Cell Myeloma	Medical College of Wisconsin	P2	CCC (50)
Gdc-0449 Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
Human Bcma Targeted T Cells Plasma Cell Myeloma	Hrain Biotechnology Co., Ltd.	P2	CCC (50)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
Inobrodib Plasma Cell Myeloma	CellCentric Ltd.	P2	CCC (50)
iopofosine (¹³¹I) Plasma Cell Myeloma	Cellectar Biosciences, Inc.	P2	CCC (50)
Olaparib Plasma Cell Myeloma	Medical College of Wisconsin	P2	CCC (50)
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 Plasma Cell Myeloma	Multiple Myeloma Research Consortium	P2	CCC (50)
Regorafenib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
Relatlimab Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CCC (50)
Trastuzumab Emtansine Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
Tucidinostat Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	P2	CCC (50)
MODERNA COVID-19 VACCINE RNA Plasma Cell Myeloma	Barbara Ann Karmanos Cancer Institute	P2	CCC (49)
gc012f Plasma Cell Myeloma	Gracell Biotechnologies (Shanghai) Co., Ltd.	P1/2	CCC (49)
Binimetinib Plasma Cell Myeloma	University of Heidelberg Medical Center	P2	CCC (48)
Descartes-08 Plasma Cell Myeloma	Cartesian Therapeutics	P2	CCC (48)
Fexagratinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CCC (48)
Ganciclovir Plasma Cell Myeloma	City of Hope Medical Center	P2	CCC (48)
Gpc-100 Plasma Cell Myeloma	GPCR Therapeutics, Inc.	P2	CCC (48)
Nirogacestat Plasma Cell Myeloma	Hellenic Society of Hematology	P2	CCC (48)
phe885 Plasma Cell Myeloma	Novartis Pharmaceuticals	P2	CCC (48)

Showing 126 to 150 of 329 assets

PreviousPage 6 of 14Next